ReviewHeliyon2024
Plant antibacterials: The challenges and opportunities.
Review in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Antibacterial Plant Secondary Metabolites: Mechanisms of Action, Pharmacokinetics, Safety, and Translational Potential.Molecules (Basel, Switzerland) · 2026Review
- UropathogenicAntibiotics (Basel, Switzerland) · 2026Review
- Ethnobotanical survey of medicinal plants traditionally used in Daulat Nagar, Punjab, Pakistan.Journal of ethnobiology and ethnomedicine · 2026Article
- Efficacy of Cannabidiol in Reducing Virulence ofInternational journal of molecular sciences · 2026Article
- Sacha Inchi (Molecules (Basel, Switzerland) · 2025Article
- The Role of Plant Oils in Combating Streptococcal Infections: Mechanisms, Efficacy, and Therapeutic Potential.Current microbiology · 2025Review
- Bioprospecting of six polyphenol-rich Mediterranean wild edible plants reveals antioxidant, antibiofilm and bactericidal properties against Methicillin resistant Staphylococcus aureus.Scientific reports · 2025Article
- Potential Application of Plant By-Products in Biomedicine: From Current Knowledge to Future Opportunities.Antioxidants (Basel, Switzerland) · 2025Review
- Review
- Mechanisms of ferroptotic and non-ferroptotic organ toxicity of chemotherapy: protective and therapeutic effects of ginger, 6-gingerol and zingerone in preclinical studies.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Antibacterial Activity of Traditional Medicinal Plants: Combating Antibiotics Resistance in Animal Wound Infections.Veterinary medicine and science · 2025Article
- Therapeutic potential of Chromolaena odorata, Vernonia amygdalina, and Cymbopogon citratus against pathogenic Bacteria.Scientific reports · 2025Article
- A Screen of Traditional Chinese Medicinal Plant Extracts Reveals 17 Species with Antimicrobial Properties.Antibiotics (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Nature possesses an inexhaustible reservoir of agents that could serve as alternatives to combat the growing threat of antimicrobial resistance (AMR). While some of the most effective drugs for treating bacterial infections originate from natural sources, they have predominantly been derived from fungal and bacterial species. However, a substantial body of literature is available on the promising antibacterial properties of plant-derived compounds. In this comprehensive review, we address the major challenges associated with the discovery and development of plant-derived antimicrobial compounds, which have acted as obstacles preventing their clinical use. These challenges encompass limited sourcing, the risk of agent rediscovery, suboptimal drug metabolism, and pharmacokinetics (DMPK) properties, as well as a lack of knowledge regarding molecular targets and mechanisms of action, among other pertinent issues. Our review underscores the significance of these challenges and their implications in the quest for the discovery and development of effective plant-derived antimicrobial agents. Through a critical examination of the current state of research, we give valuable insights that will advance our understanding of these classes of compounds, offering potential solutions to the global crisis of AMR. © 2017 Elsevier Inc. All rights reserved.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.